
Is MRNA (Moderna, Inc.) Halal or Haram?
Moderna passes the core business activity screen, as biotechnology and vaccine development are inherently permissible. However, the stock is currently classified as Doubtful because its interest income to revenue ratio sits at a high 16.15%, well above the 5% AAOIFI threshold. Fortunately, its debt-to-market cap ratio remains exceptionally low at 10.2%, easily passing the leverage screen.
Price Chart (5D)
MRNA — Last 7 Days
| Date | Open | High | Low | Close | Volume | Change |
|---|---|---|---|---|---|---|
| 2026-06-08 | 48.22 | 48.99 | 46.80 | 47.60 | 4.0M | -1.29% |
| 2026-06-05 | 50.77 | 51.53 | 46.38 | 47.44 | 6.1M | -6.56% |
| 2026-06-04 | 49.40 | 51.90 | 48.94 | 51.59 | 6.7M | +4.43% |
| 2026-06-03 | 45.30 | 49.55 | 45.30 | 49.06 | 6.9M | +8.30% |
| 2026-06-02 | 45.35 | 46.17 | 43.90 | 45.64 | 5.7M | +0.64% |
| 2026-06-01 | 47.07 | 47.07 | 44.20 | 46.06 | 6.2M | -2.15% |
| 2026-05-29 | 47.27 | 49.26 | 46.82 | 47.19 | 6.3M | -0.17% |
Discussion
Sign in to join the discussion
Loading comments...
Shariah Screening Details for MRNA
Business Activity
Permissible
Moderna's core business of developing and commercializing mRNA therapeutics and vaccines for infectious and rare diseases is considered halal and permissible under Islamic principles.
Debt / Market Cap
10.25%
Interest Income
16.15%
Cash & Securities
31.02%
About Moderna, Inc. (MRNA)
Moderna is a leading biotechnology company globally recognized for pioneering messenger RNA (mRNA) therapeutics and vaccines. Its product pipeline targets infectious diseases, immuno-oncology, and rare diseases, most notably including its widely distributed COVID-19 and respiratory syncytial virus (RSV) vaccines.
For Muslim investors, Moderna currently holds a Doubtful status under AAOIFI standards despite its halal core business. While the company easily passes the debt and cash screening criteria, it fails the interest income screen, meaning investors must carefully weigh this non-compliant revenue stream before adding it to their portfolios.
From an Islamic finance perspective, Moderna boasts a highly conservative balance sheet with a debt-to-market cap ratio of just 10.2%. However, the company generates significant interest from its massive cash reserves, pushing its interest income to revenue ratio to 16.15%, which far exceeds the strict 5% limit allowed for halal investments.
Since the primary issue is interest generated from cash rather than an impermissible core business, some investors may choose to calculate and purify these earnings. Moving forward, halal investors should monitor Moderna's revenue growth and cash management strategies to see if this interest ratio drops back below the compliance threshold.
CEO
Stéphane Bancel
Employees
5,800
IPO Date
2018-12-07
Headquarters
Cambridge, MA, US
Website
www.modernatx.comMRNA Key Financial Statistics
Revenue
$1.94B
Net Income
$-2.82B
EPS (Diluted)
$-7.26
Stock Price
47.14
Beta
1.34
52-Week Range
22.28-59.55
Total Debt
$1.92B
Total Equity
$8.65B
Current Ratio
3.29
MRNA Financial Health & Profitability
Profit Margins
Revenue Growth (YoY)
-39.2%
Prior year: $3.20B
Net Cash
$679.0M
Cash: $2.60B — Debt: $1.92B
R&D Spending
$3.13B
% of Revenue
161.1%
Frequently Asked Questions About MRNA
Is MRNA (Moderna, Inc.) stock halal to invest in?▾
What does Moderna, Inc. do?▾
What screening criteria were used for MRNA?▾
When was MRNA last screened?▾
Disclaimer
This shariah compliance assessment for MRNA (Moderna, Inc.) is provided for informational purposes only and does not constitute financial, investment, or religious advice. Screening criteria are based on widely accepted AAOIFI standards, but individual scholars may differ in their opinions. Always consult with a qualified Islamic scholar and licensed financial advisor before making investment decisions. Past screening status does not guarantee future compliance. Last screened: 2026-04-29.